genzyme
Home » Archives for genzyme
Genzyme dickers over sales deals as Sanofi dangles
Thursday, September 2nd, 2010
When Sanofi CEO Chris Viehbacher outlined his desire to buy Genzyme for $18.5 billion, he cited the biotech’s diagnostics business as one particular area that made an alliance attractive. But as Reuters notes, Viehbacher and Sanofi may never get a chance to see just how well that match-up would work, even if it does coax Genzyme into a deal. Genzyme already has the diagnostics business, along with its oncology genetics testing ops, up for sale.
Posted in: Pharma News | 0 Comments »
Read the full story
PhIII: Liver enzymes spike in 7% of mipomersen group
Wednesday, September 1st, 2010
Isis and Genzyme touted a full set of late-stage data on their cholesterol drug mipomersen , underscoring the therapy’s success in hitting its primary endpoint and detailing the issue with elevated liver enzymes seen in a slice of the drug group. Building on their release in early August, researchers found a 28 percent reduction in LDL levels in the drug group compared to a five percent increase among the placebo arm. “Having these data presented is a great milestone for the mipomersen program,” said Paula Soteropoulos, vice president and general manager of Genzyme’s cardiovascular business.
Posted in: Pharma News | 0 Comments »
Read the full story
Genzyme ready to talk M&A if the price is right
Wednesday, September 1st, 2010
Longtime Genzyme CEO Henri Termeer has taken a public stand on Sanofi’s low ball offer: “At $69 a share, the current offer, the company is not for sale,” he tells the Wall Street Journal . In fact, he expects the board to open up the process and seek a White Knight, or at least some new offer that would drive the price up high enough to whet Termeer’s interest. Termeer was countering Sanofi’s “bear hug” letter, released on Sunday
Posted in: Pharma News | 0 Comments »
Read the full story
Genzyme Sale Inevitable, Buysiders Say
Wednesday, September 1st, 2010
Sooner or later Sanofi-Aventis will cough up more cash and buy Genzyme, predicts a group of healthcare investors.
Posted in: headlines | 0 Comments »
Read the full story
Sanofi Still Bidding for Genzyme – And at the Same Price
Tuesday, August 31st, 2010
Derek Lowe submits: Well, so much for my fantasy of Sanofi-Aventis ( SNY ) walking away from their attempt to buy Genzyme ( GENZ ). They went public Sunday with a $69/share offer – even lower than most people were thinking – and just a little while ago, Genzyme publicly turned them down
Posted in: Pharma News | 0 Comments »
Read the full story
Genzyme rejects Sanofi’s $18.5B offer
Monday, August 30th, 2010
Sanofi-Aventis has finally gone public with its offer for Genzyme. But
Posted in: Pharma News | 0 Comments »
Read the full story
How About The Same Price You Turned Down Before? Hmm?
Monday, August 30th, 2010
Well, so much for my fantasy of Sanofi-Aventis walking away from their attempt to buy Genzyme. They went public yesterday with a $69/share offer – even lower than most people were thinking – and just a little while ago, Genzyme publicly turned them down . What’s more, this is apparently the same price at which Genzyme (privately) balked earlier in the summer
Posted in: Clinical Trials | 0 Comments »
Read the full story
Sanofi Takes Its Bid To Genzyme Shareholders
Sunday, August 29th, 2010
After weeks of leaks, Sanofi-Aventis has made public its offer to buy up Genzyme by going directly to shareholders of the beleaguered biotech. The $18.5 billion, all-cash deal comes after Sanofi ceo Christopher Viehbacher claims he has been stonewalled by Genzyme chairman and ceo Henri Termeer.
Posted in: Regulatory | 0 Comments »
Read the full story
Genzyme shortages ease
Saturday, August 28th, 2010
Genzyme has sent a letter to U.S. patients of its enzyme replacement therapies of rare diseases, letting them know that they will be receiving more doses of medicine than they have for the past… The Boston Globe – Genzyme will double shipments of rationed drugs Mass High Tech – Genzyme eases drug shortage with increased shipments
Posted in: headlines | 0 Comments »
Read the full story
Sanofi-Aventis and Genzyme: Walking Away?
Friday, August 27th, 2010
Here’s a roundup of the latest reports on the potential Genzyme takeover. For one thing, it looks as if people on the inside are talking again, after a good period of silence.
Posted in: Clinical Trials | 0 Comments »
Read the full story
Business Week – Drug Marketing
Business Week – Pharma Marketing
Cafe Pharma
Clinical Trials.gov
FDA on Twitter
Pharma Live
Pharma Voice